Genomic Health Licenses Almac's Technology to Develop New Test | GenomeWeb

NEW YORK (GenomeWeb News) – Genomic Health said after the close of the market on Monday that it is exclusively licensing Almac Group's technology and intellectual property to develop a multi-gene test for the prediction of benefits from DNA damage-based chemotherapy drugs.

Genomic Health will also validate and validate the test, which is focused on drugs such as the commonly used anthracycline-based regimens. The company said such a test would be especially useful for high-risk breast cancer patients who are eligible for chemotherapy based on their Oncotype DX score.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.